ORIONS Money Stocks

[BioSpecialist]

HGEN =Phase 3 data for Covid 19 Drug very soon ,first results shows its more effective than Gileads drug ..Could be approved before year end if phase 3 is successful this would push the stock likely toward 30 dollar (current price $5)

"Humanigen's Lenzilumab Shows Promising Results In COVID-19 Trial

An analysis of the first clinical use of Humanigen Inc.'s (HGEN) investigational drug Lenzilumab in twelve COVID-19 patients has shown some encouraging results.

Lenzilumab is designed to prevent and/or treat cytokine storm that precedes severe lung dysfunction and ARDS (acute respiratory distress syndrome) in serious cases of SARS-CoV-2 infection.

Patients treated with Lenzilumab showed rapid clinical improvement with a median time to improvement of five days and a median time to recovery of five days. In comparison, patients treated with Gilead's Remdesivir demonstrated a median time to the improvement of 10 to 11 days and a median time to recovery of 10 to 11 days.

Remdesivir was granted emergency use authorization based on time to recovery of 11 days in the Adaptive COVID-19 Treatment Trial (ACTT-1).

A potential registrational phase III study of Lenzilumab in COVID-19 patients is currently enrolling. "